L
Lorraine A. Fitzpatrick
Researcher at GlaxoSmithKline
Publications - 189
Citations - 15281
Lorraine A. Fitzpatrick is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Osteoporosis & Parathyroid hormone. The author has an hindex of 58, co-authored 189 publications receiving 14301 citations. Previous affiliations of Lorraine A. Fitzpatrick include Mayo Clinic & Columbia University.
Papers
More filters
Journal ArticleDOI
Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta
Edwin M. Horwitz,Darwin J. Prockop,Lorraine A. Fitzpatrick,Winston W.K. Koo,Patricia L. Gordon,Michael D. Neel,Michael D. Sussman,Paul J. Orchard,Jeffrey C. Marx,Reed E. Pyeritz,Malcolm K. Brenner +10 more
TL;DR: Improvements in total body bone mineral content and growth velocity were associated with increases in growth velocity and reduced frequencies of bone fracture, indicating the feasibility of allogeneic bone marrow transplantation in the treatment of osteogenesis imperfecta and perhaps other mesenchymal stem cell disorders as well.
Journal ArticleDOI
Coronary Artery Calcium Area by Electron-Beam Computed Tomography and Coronary Atherosclerotic Plaque Area A Histopathologic Correlative Study
TL;DR: This histopathologic study confirms an intimate relation between whole heart, coronary artery, and segmental coronary atherosclerotic plaque area and EBCT coronary calcium area but suggests that there is a threshold value for plaque area below which coronary calcium is either absent or not detectable by this methodology.
Journal ArticleDOI
Arterial calcification and not lumen stenosis is highly correlated with atherosclerotic plaque burden in humans: A histologic study of 723 coronary artery segments using nondecalcifying methodology
Giuseppe Sangiorgi,John A. Rumberger,Arlen R. Severson,William D. Edwards,Jean Grégoire,Lorraine A. Fitzpatrick,Robert S. Schwartz +6 more
TL;DR: Coronary calcium quantification is an excellent method of assessing atherosclerotic plaque presence at individual artery sites and the remodeling phenomenon is the likely explanation for the lack of a good predictive value between lumen narrowing and quantification of mural calcification.
Journal ArticleDOI
Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta
Edwin M. Horwitz,Darwin J. Prockop,Patricia L. Gordon,Winston W.K. Koo,Lorraine A. Fitzpatrick,Michael D. Neel,M. Elizabeth McCarville,Paul J. Orchard,Reed E. Pyeritz,Malcolm K. Brenner +9 more
TL;DR: Clinical responses of the first children to undergo allogeneic bone marrow transplantation (BMT) for severe osteogenesis imperfecta, a genetic disorder characterized by defective type I collagen, osteopenia, bone fragility, severe bony deformities, and growth retardation, are described.
Journal ArticleDOI
Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial
Paul D. Miller,Gary Hattersley,Bente Juel Riis,Gregory C. Williams,Edith M. C. Lau,Luis A. Russo,Peter Alexandersen,Cristiano Augusto de Freitas Zerbini,Ming-yi Hu,Alan G. Harris,Lorraine A. Fitzpatrick,Felicia Cosman,Claus Christiansen +12 more
TL;DR: Among postmenopausal women with osteoporosis, the use of subcutaneous abaloparatide, compared with placebo, reduced the risk of new vertebral and nonvertebral fractures over 18 months.